A recent study demonstrated that the antibody-mediated neutralization of IL-1β significantly enhanced the antitumor activity of an anti-PD-1 antibody, which was accompanied by increased tumor infiltration by CD8+ T cells, indicating that targeting IL-1β has a beneficial effect on PDAC therapy outcomes59. The gene discussed is CD8A; the disease is neoplasm.